$CDNA

Goldberg Michael sold $2.1M of CDNA

Goldberg Michael sold 44,700 shares of CareDx, Inc. (CDNA) at $47.06 ($2.10M total) on 2026-08-04.

Original reporting
SEC EDGAR · Goldberg Michael
Published Aug 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 7:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CDNA
Neutral
medium confidence
Mentioned
$CDNA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDNANeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale size, price, and post-transaction holdings. It may influence short-term sentiment but does not provide new operational or financial information about CareDx.

02

Market read

Traders may note insider selling as a minor sentiment input, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The article does not state whether the director’s remaining holdings or future planned sales change, nor does it provide context like option exercises, tax events, or pre-scheduled trading beyond noting no 10b5-1 plan.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-06 after the sale on 2026-08-04

Background

The article is a SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA).

Company-level read

Ticker impact

$CDNANeutralMedium confidence
Context

CareDx director Michael Goldberg filed a Form 4 selling 44,700 shares at $47.0581 on 2026-08-04, totaling about $2.10M.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small unless follow-on selling appears.

Evidence & confidence

The filing is primary-source and time-stamped, but it does not include new company performance, guidance, or regulatory/contract developments. Insider sales are common and often non-informational, though the absence of a stated 10b5-1 plan can increase interpretive sensitivity.

Market effects

No sector-wide signal; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity or diversification, especially since the filing does not allege misconduct or tie the sale to any new negative event.

Key entities

  • CareDx, Inc.

    Subject of the Form 4 insider transaction disclosure (CDNA).

  • Michael Goldberg

    Director who sold 44,700 shares in an open-market transaction.

  • SEC Form 4

    Primary-source insider transaction report filed on 2026-08-06.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CDNAMed

CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?

CareDx (CDNA) shares rose 13% to $61.37 on high volume, following a price target increase to $74 by BTIG. Q2 2026 revenue grew 52% YoY, with testing services up 61%. Q3 earnings are expected at $0.24 per share, down 14.3% YoY, and revenue at $122.35M, up 22.3% YoY. The stock has a Zacks Rank of #2 (Buy). Charles River Laboratories (CRL), another medical services company, closed up 6.2% at $294.44, with a Zacks Rank of #2 (Buy).